• AbbVie flagged new Phase 3 CLL14 data for VENCLEXTA/VENCLYXTO in first-line chronic lymphocytic leukemia at the EHA 2026 Congress.
• Results were presented at the meeting, highlighting nine-year follow-up from a fixed-duration venetoclax regimen.
• The study showed longer-lasting disease control and a longer interval before additional treatment versus a comparator chemoimmunotherapy regimen.
• AbbVie pointed to a safety profile consistent with earlier use, with blood-count suppression and infections among the key serious risks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606120300PR_NEWS_USPR_____CG80017) on June 12, 2026, and is solely responsible for the information contained therein.